Phase II study of apatinib, a novel tyrosine kinase inhibitor targeting tumor angiogenesis, as second-line treatment for recurrent or advanced cervical cancer patients-Reference-Cited by-同舟云学术

Phase II study of apatinib, a novel tyrosine kinase inhibitor targeting tumor angiogenesis, as second-line treatment for recurrent or advanced cervical cancer patients

Published:2019-10-21 Issue:4 Volume:38 Page:1186-1191
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Zhang Linlin,Chen Liang,Yu Hao^ORCID

Funder

Shandong traditional Chinese medicine science technology development projects

science and technology subject of Shandong health care technology association

the key research and development program of Shandong Province.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10637-019-00858-5.pdf

Reference22 articles.

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359–E386. https://doi.org/10.1002/ijc.29210

2. Pfaendler KS, Tewari KS (2016) Changing paradigms in the systemic treatment of advanced cervical cancer. Am J Obstet Gynecol 214(1):22–30. https://doi.org/10.1016/j.ajog.2015.07.022

3. Lorusso D, Ferrandina G, Pignata S, Ludovisi M, Vigano R, Scalone S, Scollo P, Breda E, Pietragalla A, Scambia G (2010) Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group. Ann Oncol 21(1):61–66. https://doi.org/10.1093/annonc/mdp266

4. Yan X, Wang Q, Wang H, Li P, Zhang G, Zhang M, Zheng X, Yang J, Zhang X, Ma Z (2019) Apatinib as maintenance therapy in extensive-stage small-cell lung cancer: results from a single-center retrospective study. J Cancer Res Clin Oncol 145(1):235–240. https://doi.org/10.1007/s00432-018-2764-8

5. Liang L, Wang L, Zhu P, Xia Y, Qiao Y, Wu J, Zhuang W, Fei J, Wen Y, Jiang X (2018) A pilot study of Apatinib as third-line treatment in patients with heavily treated metastatic colorectal Cancer. Clin Colorectal Cancer 17(3):e443–e449. https://doi.org/10.1016/j.clcc.2018.02.011

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combat Against Gynecological Cancers with Blood Vessels as Entry Point: Anti-Angiogenic Drugs, Clinical Trials and Pre-Clinical Nano-Delivery Platforms;International Journal of Nanomedicine;2023-06

2. Investigational drugs for recurrent or primary advanced metastatic cervical cancer: what is in the clinical development pipeline?;Expert Opinion on Investigational Drugs;2023-03-04

3. Integrative analysis of multi-omics data reveals inhibition of RB1 signaling promotes apatinib resistance of hepatocellular carcinoma;International Journal of Biological Sciences;2023

4. Efficacy and Safety of Apatinib for the Treatment of Advanced or Recurrent Cervical Cancer: A Single-Arm Meta-Analysis Among Chinese Patients;Frontiers in Pharmacology;2022-08-11

5. A Retrospective Cohort Study Evaluates Clinical Value of Anlotinib in Persistent, Metastatic, or Recurrent Cervical Cancer After Failure of First-Line Therapy;Drug Design, Development and Therapy;2021-11